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ABSTRACT 
 
 
Background: In recent years, epigenetics has gained interest among 
scientists involved in different research areas (e.g. cancer, molecular 
medicine, behavior, development). It is now clear that the 
environment influences the methylome promoting methylation 
variation with possible effects on both healthy and disease-related 
phenotypes. I studied inter-individual DNA methylation variation in 
healthy individuals and in cancer tissues to identify possible factors 
influencing this variation. 
 
Results: Using the EPIC-Italy dataset (1 tissue, 83 males and 83 age-
matched healthy females), I analyzed methylation variation values in 
relation to CpG cluster density and I found a strong association 
between them (p-value < 2.2*10-16). Furthermore, I found that genes 
related to CpGs with high methylation variation values were enriched 
for immunological pathways; instead, those associated with low ones 
were enriched for pathways related to basic cellular functions. Finally, 
I found an association between methylation variation values and 
signals of both ancient (p-value < 2.2*10-16) and recent selective 
pressure (p-value < 1*10-4). Furthermore, using TCGA datasets (4 
healthy and cancer tissues), I analyzed methylation variation 
correlation among different tissues and different statuses; I found that 
cancer tissues show increased correlation among them and higher 
methylation variation than healthy tissues (p-value < 2.2*10-16). 
Finally, I used a linear regression model to calculate Differentially 
Methylated CpGs (DM-CpGs) and I found that DM-CpGs always 
show higher inter-individual methylation variation especially in 
cancer (p-value < 2.2*10-16). 
 
Conclusion: My results indicate the presence in healthy subjects of an 
intricate interplay between genetics, epigenetics and evolutionary 
constraints that influence the inter-individual methylation variation. 
Furthermore, my results show an increase of inter-individual variation 
in cancers. 
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Abbreviations 
 
• BLCA= Bladder Urothelial Carcinoma 
• BRCA= Breast invasive carcinoma  
• dbPSHP= DataBase of recent Positive Selection across 
Human Populations 
• DM-CpGs= Differentially Methylated – CpGs 
• DNMT= DNA methyltransferase  
• GERP-RS= Genomic Evolutionary Rate Profiling - Rejected 
substitutions  
• GSEA= Gene Set Enrichment Analysis  
• HCs = High-density Clusters 
• ICs= Intermediate-density Clusters 
• KIRC= Kidney renal clear cell carcinoma 
• LCs= Low-density Clusters 
• LIHC= Liver hepatocellular carcinoma 
• MV= Inter-individual methylation variation 
• PBMC= Peripheral blood mononuclear cells 
• SAM= S-adenosyl-methionine  
• TCGA= The Cancer Genome Atlas 
• TET= Ten-Eleven-Translocation  
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1. INTRODUCTION 
 
1.1 DNA methylation 
 
Genetics is described as the field that studies the heritable changes in 
gene activity due to the direct alteration of the DNA code. In contrast, 
epigenetics studies the changes in gene activity that are not associated 
with any direct alteration of the DNA sequence itself (Moore et al. 
2013). The epigenetic changes result from a set of, usually, reversible 
modifications and include: nucleic acid modification, chromatin 
remodeling and histone modification (Allis C, Jenuwein T, Reinberg 
D 2007). Methylation is one of the major epigenetic modification on 
DNA in almost all living organisms (Scarano et al. 2005). It usually 
occurs on CpGs dinucleotides, but, in many organisms and in a low 
percentage, it could also occur at different sites (Scarano et al. 2005). 
This modification consists of an addition of a methyl group (CH3) at 
the 5th position of the cytosine moiety (Kulis and Esteller 2010). The 
reaction is catalyzed by DNA methyltransferase (DNMT) family 
proteins in the presence of S-adenosyl-methionine (SAM) (Kulis and 
Esteller 2010). DNA demethylation, instead, could be obtained either 
passively, by the not methylation of the new strand during DNA 
replication, or actively, by other enzymes (e.g. Ten-Eleven-
Translocation (TET) family proteins) that have not yet been 
completely identified (Chen and Riggs 2011). Undoubtedly, 
methylation main function is to regulate gene transcription according 
to the environmental changes and to the cell needs (Moore et al. 
2013). In brief, the presence of methylation near the promoter region 
of a gene is usually associated with gene transcription repression; 
instead, the presence of methylation in gene body is correlated with 
activation of gene transcription (Moore et al. 2013; Yang et al. 2014). 
Even if its role on DNA is well characterized (Moore et al. 2013), new 
findings are extending its possible biological implication (e.g. cancers 
and transgenerational inheritance) (Jeltsch and Jurkowska 2014). 
Indeed, methylation and demethylation processes, the hereditability of 
the methylation pattern, and the implication in tumorigenesis and in 
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many other diseases are still not completely known (Kulis and Esteller 
2010; Moore et al. 2013). 
 
1.2 The different roles of the DNA methylation in biological 
processes 
 
Until now, methylation seems to be implicated in different biologic 
functions and the scientific community put a lot of effort into 
achieving a full knowledge of it. 
Many studies pointed out the role of methylation in tissue 
differentiation and embryonic development (Smith and Meissner 
2013) focusing on how methylation changes on DNA allow 
pluripotent stem cells to differentiate and develop in different organs. 
All the papers that study the role of methylation in X-inactivation and 
imprinting in the early stages of the embryonic development can be 
broadly included this group (Santos and Dean 2004). 
Other studies focused their attention on its possible role in cancer 
development and tumorigenesis (Kulis and Esteller 2010). In brief, 
how methylation alterations could induce tumorigenesis and how it is 
possible, correcting them, to kill cancer cells and heal the patient. This 
role, as it is possible to imagine, aroused the interest of all the 
scientific community and much data about methylation in cancer are 
freely available on public databases. However, the role of methylation 
in the pathogenesis of the cancer is still under debate, because 
aberrant methylation patterns can be sometimes found as the result of 
the carcinogenesis and not as the cause (Scarano et al. 2005; Kulis and 
Esteller 2010). The most common observed DNA methylation 
changes in human cancer are the loss of global methylation 
(hypomethylation), and the addition of methylation 
(hypermethylation) in CpG Island regions (Pfeifer 2018). These 
alterations cause the inactivation of specific genes (that normally are 
active) and the global activation of all the others (Pfeifer 2018). 
Recently, many papers suggested a possible new methylation role in 
evolution (Jeltsch and Jurkowska 2014). The starting idea was based 
on evidence that methylation patterns on DNA could be transmitted 
through generations (Szyf 2015). The hypothesis that methylation 
patterns could persist across generations seems to be counterintuitive, 
especially considering the demethylation process that occurs during 
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the epigenetic reprogramming in the mammal’s embryonic 
development (Soubry 2015). However, despite this consideration, 
there is emerging evidence showing that methylation could be 
inherited over generations (Szyf 2015). Indeed, epigenetic changes 
could explain the inheritance of some parentally acquired traits that 
cannot be explained by Mendelian inheritance, genetic damages or 
DNA mutations (Soubry 2015).  
In conclusion, DNA methylation seems to be involved in many 
biological functions and new discoveries, day by day, are expanding 
our overall idea about it. 
 
1.3 The inter-individual Methylation Variation 
 
DNA methylation as one of the principal interfaces between our 
genome and the environment can be invoked to explain phenotypic 
variations in humans (Leenen et al. 2016). 
A better understanding of how methylation varies among humans is 
required not only for a theoretical point of view but also from a 
practical one (Bock et al. 2008). Undeniably, knowing the natural 
changes in DNA methylation among healthy people could help us to 
identify the boundary between healthy and deleterious variations 
(Bock et al. 2008). However, until now, only a few papers focused 
their attention on inter-individual DNA methylation variation. A 
reason could be that it is difficult to analyze such variable biological 
processes due to a large number of factors that could modify them. 
Indeed, also in the same population, many variables could promote 
methylation variation such as age, gender, stress, food intake, and 
health status (Zhang et al. 2011; Heyn et al. 2013; Chatterjee et al. 
2015; Jones et al. 2015). 
Different methods are used to evaluate the methylation status of CpGs 
on DNA in order to understand the amount of methylation, how it 
changes, and how it modifies gene transcription. One of the most used 
techniques is the Illumina 450K methylation array. This array allows 
researchers to probe hundreds of thousands of CpGs in one shot. The 
fluorescence signal used in the array is then converted into a number 
(called beta-value) that ranges from 0 (unmethylated) to 1 
(methylated). Thus, most of the CpGs in a sample fall near 0 or 1. 
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Figure 1 shows an example of a normal methylome (the entire set of 
CpGs methylation status in a sample). 
 
 
 
 
Figure 1. Beta-value density plot of a normal sample. Beta-values 
from 0 to 1 (x-axis) and their frequency (y-axis) are plotted.  
 
It is possible to note that the majority of beta-values fall near to 0 or 1 
but there are a good number of probes that fall in the middle range. 
These probes are considered partially methylated and they are usually 
the result of allelic methylation or strand-specific methylation 
(Teschendorff et al. 2013). 
During years, many datasets of methylomes have been stored and 
made available to the scientific community. Thanks to this sharing 
mood, we are now able to look at the methylation status of thousands 
of CpGs among hundreds of people and between different 
populations. 
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2. AIM 
 
In this thesis, I decided to explore the CpGs inter-individual 
methylation variation (MV) exploiting public methylation arrays data. 
I focused on two major aims: 
 
1) finding whether inter-individual methylation variation is 
associated with evolutionary signals 
 
2) describing inter-individual methylation variation in cancers. 
 
In particular, for the first aim, I decided to investigate the presence of 
ancient and recent selective pressure signals using inter and intra-
species conservation measures respectively. For the second aim, I 
decided to assess the MV trend in cancer and in Differentially 
Methylated - CpGs. In detail, I analyzed the MV trend in different 
tissues, and between cancers and control samples. However, I also 
decided to achieve other minor aims: I assessed a possible MV 
biological role and defined its genomic context. 
In conclusion, in my thesis, I explored novel factors influencing inter-
individual methylation variation and underlined its biological role in 
healthy and not healthy tissues. 
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3. MATERIALS AND METHODS 
 
3.1 EPIC dataset preprocessing 
 
In the first part of this thesis, Illumina 450K data of 845 people from 
the EPIC-Italy cohort were downloaded from the GEO database 
(GSE51032). The entire dataset was produced at the Human Genetics 
Foundation (HuGeF) in Turin (Italy), and it contains raw data and 
normalized methylation values (beta-values) from peripheral blood 
cells of 188 men and 657 women (Riboli et al. 2002). All the 
methylation values from the EPIC dataset were normalized by the 
consortium using a standard routine (Riboli et al. 2002). In particular: 
GenomeStudio software was used for background subtraction and dye 
bias correction, while COMBAT software (Demetriou et al. 2013; van 
Veldhoven et al. 2015) was used to correct batch effects. Finally, to 
test if white blood cell composition could influence the inter-
individual methylation variation in these data, I performed the same 
method described by van Veldhoven et al. 2015 (van Veldhoven et al. 
2015). In brief, the CpGs that differed significantly between each 
individual cell type and the Peripheral blood mononuclear cells 
(PBMC) using the Reinius et al. dataset (GSE35069) (Reinius et al. 
2012) were identified. I used a linear regression approach (limma) 
(Ritchie et al. 2015) on R to calculate differential methylation 
between CpGs with the following thresholds: p < 1e-07 and logFC > 
0.05. No notable differences were assessed before and after the 
filtering of the 8452 CpGs influenced by the white blood cell 
variability. Therefore, in this thesis, I performed all the calculations 
without white blood cell variability correction. Four participants were 
excluded from the EPIC dataset due to age or sex incongruities 
according to J. H. Kim and colleagues (Kim et al. 2016). Finally, 83 
healthy males and 83 age-matched healthy females were selected from 
the entire cohort (age range = 36 - 65). This subset was created to 
obtain a good match between genders and ages because the 
methylation variation could be influenced by age and sex (Zhang et al. 
2011; Jones et al. 2015). Out of 485512 CpGs, 127616 were excluded 
from this work for two reasons: a) CpGs falling on sex chromosomes 
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or on SNPs and b) CpGs showing cross-reactivity or polymorphisms 
(Chen et al. 2013; Price et al. 2013). The standard deviation was 
chosen as a measure to study CpGs inter-individual methylation 
variation (MV). Since this thesis was specifically focused on 
variation, I decided to use only the CpGs with methylation values 
estimated in all samples. Therefore, I excluded all the CpGs with 
missing values. 206441 CpGs were obtained at the end of the filtering 
process. To obtain MV values, mean, variance and standard deviation 
values of all samples for each CpGs were calculated. To associate 
each MV value to a CpG density cluster, the association provided by 
Price and colleagues (Price et al. 2013) was used. 
 
3.2 TCGA datasets preprocessing 
 
In the second part of this thesis, Illumina 450K methylation data of 
four cancer tissues from TCGA were exploited. In particular, 892 
methylomes for breast cancer dataset (BRCA), 430 for liver cancer 
dataset (LIHC), 440 for bladder cancer dataset (BLCA) and 485 for 
kidney cancer dataset (KIRC) were downloaded. In each dataset, 
cancer methylomes and healthy control methylomes are present. 
As previously done with the EPIC dataset, 127616 CpGs were filtered 
out because: falling on sex chromosomes or on SNPs, showing cross-
reactivity or polymorphisms. Since this thesis was specifically 
focused on variation, as done before, only the CpGs with methylation 
values present in all samples were used and all the CpGs with missing 
values were not included in the analysis. Also for these datasets, 
mean, variation and standard deviation of each CpGs in each tissue 
were calculated from beta-values. The standard deviation was chosen 
as a measure for MV. 
 
3.3 The Gene Set Enrichment Analysis 
 
To explore the link between genes function and CpGs’ MV values, I 
performed a Gene Set Enrichment Analysis (GSEA). Only the CpGs 
that fell in a range of 1500 base pairs before and after the 
Transcription Start Site (TSS) (-1500, +1500) were selected. The 
resulting CpGs were linked to a gene according to Price criteria (Price 
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et al. 2013). Then, MV values of CpGs that were associated with the 
same gene were mediated. To use the GSEAPreranked module on 
GenePattern (Reich et al. 2006), I transformed all the MV values in a 
z-score using this formula: 
 
z = ((X-µ))/σ 
 
where z is the z-score, X is the MV value of that gene, µ is the 
population MV mean, and σ is the standard deviation of all the MV 
values. Using this linear transformation, positive and negative values 
were obtained and sorted from the higher to the lower. I decided to 
use the KEGG gene set (“c2.cp.kegg.v5.1.symbols.gmt [Curated]”) to 
perform the enrichment analysis. All the gene sets that were enriched, 
at the same time, with a nominal p-value ≤ 0.01 and with an FDR q-
value ≤ 0.25 were considered statistically significant. 
 
3.4 Analysis of ancient selective pressure signals 
 
To evaluate the presence of ancient selective pressure, a widely 
accepted conservation-based method was used: Genomic 
Evolutionary Rate Profiling - Rejected substitutions (GERP-RS) 
(Cooper et al. 2005). Briefly, the GERP-RS score calculates the 
conservation of each nucleotide in a multi-species alignment of 35 
mammals to the human genome 19 (hg19). For each DNA base, it 
associates a “rejected substitutions” score that ranges from a 
maximum of 6.18 to a minimum of -12.36. After downloading the 
entire GERP-RS track (GRCh37/hg19) from the UCSC database, 
GERP-RS scores were intersected with CpGs position using 
BEDTOOLS (Quinlan and Hall 2010). Thus, I obtained a GERP-RS 
score for each CpG of my dataset. A GERP-RS score near zero 
represents no substitution deficit and no signs of base conservation; 
instead, positive GERP-RS scores represent a substitution deficit, thus 
indicating that a base could be conserved. However, negative GERP-
RS scores are difficult to interpret (Cooper et al. 2005). For this 
reason, all the CpGs that were related to a negative GERP-RS were 
eliminated; therefore a total number of 80098 CpGs with a GERP-RS 
score ≥ 0 were analyzed. 
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3.5 Analysis of recent selective pressure signals 
 
To evaluate the presence of recent selective pressure a collection of 
different measures were used. SNPs from the DataBase of recent 
Positive Selection across Human Populations (dbPSHP) (Li et al. 
2014) were extracted. dbPSHP contains lists of positive selected SNPs 
from the 1000 Genomes Project and HapMap III, defined according to 
the following parameters:  
 
- Derived Allele Frequency (DAF) > 0.05 
- Genotype Frequency of Homozygous Derived Allele (GFHOM1) > 
0.001 
- Genotype Frequency of Heterozygote (GFHET) > 0.05 
- P-value cutoff of Hardy-Weinberg equilibrium (HWE2) > 0.0001 
- Heterozygosity (HET) < 0.5 
- Nucleotide Diversity (PI) < 0.5 
- Difference of Derived Allele Frequency (DDAF) > 0.2 
- Tajima’s D (TD) < 0 
- Fixation Index (FST1) > 0.05 
- Integrated Haplotype Score (UIHS) > 1.5 
- Cross-Population Extended Haplotype Homozygosity (UXPEHH) > 
1 
- Cross-Population Composite Likelihood Ratio (XPCLR) > 5 
 
Since the population contained within the EPIC dataset is composed 
of Italians, SNPs from populations with low genetic distance from my 
cohort were used. Therefore, I included in the analysis only SNPs 
from TSI (Tuscany, Italy) and CEU (US residents with European 
ancestry) populations. Since for each population two different SNP 
datasets exist (1000k genomes and HapMap III), they were combined, 
thus obtaining one final dataset for each population. CpGs placed in a 
range of 2000 base pairs around each filtered SNP were named as 
Recent Selective Pressure-CpGs (RSP-CpGs). RSP-CpGs were 
recognized using BEDTOOLS (Quinlan and Hall 2010). Eventually, I 
obtained 272 CpGs for TSI and 328 CpGs for CEU. 
Because the two datasets (CEU and TSI) differ for length from the 
remaining CpGs (named “Not RSP-CpGs”), I also performed a 
bootstrapping analysis. In brief, RSP-CpGs MV values were 
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compared with 10000 samples of the same population size (272 CpGs 
for TSI and 328 CpGs for CEU), randomly extracted from the 
population of Not RSP-CpGs. 
 
3.6 Correlation matrices of inter-individual Methylation Variation 
 
To assess the MV correlations among tissues between cancer and 
healthy groups, the standard deviation values of the TCGA beta-
values were exploited. Two different Pearson correlation matrices 
were produced, one for each group. Significance was tested using 
corr.test function on R. In detail, a test using “Pearson's product 
moment correlation coefficient” was performed on paired MV 
distributions. Corrplot package on R was used to draw graphs. 
 
3.7 DM-CpGs analysis 
 
To extrapolate DM-CpGs between cancer and healthy samples within 
the same tissue a linear regression approach on the CpGs was used. In 
particular, limma package (Ritchie et al. 2015) on R was used and the 
methylation beta-values were transformed in m-values using the 
following equation: 
 
M=log2(β/(1-β)) 
 
where M is the transformed methylome and β is the original beta-
value methylome. After limma approach, significant DM-CpGs were 
filtered using the following criteria: adjusted p-value < 0.01 and 
absolute logFC > 2. 11599 DM-CpGs in breast cancer (BRCA), 
20020 in the bladder (BLCA), 5294 in the kidney (KIRC), and 19039 
in the liver (LIHC) were found. To assess whether DM-CpGs have 
higher MV values than Not DM-CpGs, the standard deviation for each 
CpGs in each tissue was calculated. 
 
3.8 Statistical analyses 
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All the calculations, the statistical analyses, the correlations, the plots, 
and the bootstrapping estimations were achieved using R statistical 
package version 3.2.5, with an alpha value set for p < 0.05.
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4. RESULTS 
 
In this thesis, the CpGs inter-individual methylation variation (MV) 
was investigated in relation to evolutionary signatures, health status, 
genomic context, and biological function. To achieve these results, the 
CpGs standard deviation was used as a measure to analyze MV. 
Freely available Illumina 450k methylomes data from EPIC-Italy 
consortium on GEO (GSE51032) and four healthy and cancer 
methylomes data from TCGA were exploited. 
 
4.1 The inter-individual Methylation Variation is associated with 
CpG cluster density 
 
The first part of this thesis was focused on analyzing the CpGs inter-
individual methylation variation in the EPIC-Italy cohort and its 
relation to the genomic context, the evolutionary signals, and its 
possible biological function (Palumbo et al. 2018). The nature of this 
dataset is suitable for these aims because all the samples come from 
one tissue (blood), are the same ethnicity (Caucasian), and 
information about age, sex, and health status during years is available. 
This information allowed me to reduce possible variation sources as 
ethnicity, age, sex or the health status selecting 83 males and 83 age-
matched healthy females. 
The first step was to analyze the MV trend in this reduced cohort. In 
Figure 2, it is possible to see the distribution of MV values in the 
EPIC cohort.  
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Figure 2. MV distribution of the 206441 CpGs of the reduced EPIC-
Italy cohort. 
 
Figure 3 shows the comparison between methylation beta-values and 
MV values. For the latter continuous beta-values were binned in 
deciles. 
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Figure 3. MV values boxplots for beta-values deciles. 
 
I found that MV values were related to CpGs methylation levels (One-
Way Test; p-value < 2.2*10-16).  
In particular, CpGs with intermediate methylation levels show higher 
MV values, while CpGs with methylation values near the beta-value 
limits (0 and 1) show lower MV values.  
The second step was to analyze the association between MV values 
and the CpGs genomic context. To fulfill this aim, MV values in 
relation to CpG cluster density were analyzed. The genomic regions 
were classified according to their CpGs content into three groups: 
high-density (HCs, CG content > 55%, Obs/Exp CpG ratio > 0.75 and 
length > 500 base pairs), intermediate-density (ICs, CG content > 
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50%, Obs/Exp CpG ratio > 0.48 and length > 200 base pairs) and low-
density (LCs, non-HC/IC regions) as suggested by Price and 
colleagues (Price et al. 2013). 
In this dataset, 61946 CpGs fall in HCs, 72496 in ICs and 71999 in 
LCs. Figure 4 shows the association between CpGs MV and their 
cluster density.  
 
 
 
 
Figure 4. Boxplots of CpGs cluster density group with their MV. 
 
I found that inter-individual methylation variation values showed a 
strong association with CpGs cluster density (One-Way Test, p-value 
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< 2.2*10-16). In particular, CpGs falling in the HCs showed the lowest 
MV values, while, those classified as LCs showed the highest ones. 
Eventually, CpGs belonging to ICs showed intermediate MV values. 
These results, taken together, show that CpGs inter-individual 
methylation variation is strongly related to the surrounding genomic 
landscape and that the most variable CpGs in a population fall in the 
middle of the beta-values distribution. 
 
4.2 Functional annotations of genes associated with different inter-
individual Methylation Variation 
 
The strong relation between genomic features and MV allowed me to 
consider the existence of a possible MV biological role. To achieve 
this aim, functional annotations of genes containing CpGs with 
different inter-individual methylation variation were performed. To 
associate each gene with an MV value, 99376 CpGs located in 
genomic regions of 3000 base pairs around each Transcription Start 
Site (TSS) were selected. This approach generated a ranked list of 
genes with MV values of CpGs located in their promoter regions. 
Furthermore, using the previously created ranked list, I performed a 
Gene Set Enrichment Analysis (GSEA) (Mootha et al. 2003, 
Subramanian et al. 2005) with KEGG pathway as gene set. GSEA 
results pointed out that 18 KEGG pathways are enriched (NOM p-
value ≤ 0.01 and FDR q-value ≤ 0.25) in CpGs with high and 15 with 
low MV values (Table 1). 
 
 
Gene set name NOM p-val FDR q-val MV 
OLFACTORY TRANSDUCTION 0.000 0.000 High 
GRAFT VERSUS HOST DISEASE 0.000 0.000 High 
ALLOGRAFT REJECTION 0.000 0.000 High 
ASTHMA 0.000 0.000 High 
TYPE I DIABETES MELLITUS 0.000 0.000 High 
NEUROACTIVE LIGAND RECEPTOR 
INTERACTION 0.000 0.000 High 
AUTOIMMUNE THYROID DISEASE 0.000 0.000 High 
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INTESTINAL IMMUNE NETWORK FOR 
IGA PRODUCTION 0.000 0.001 High 
METABOLISM OF XENOBIOTICS BY 
CYTOCHROME P450 0.000 0.018 High 
ANTIGEN PROCESSING AND 
PRESENTATION 0.005 0.032 High 
DRUG METABOLISM CYTOCHROME P450 0.004 0.035 High 
CELL ADHESION MOLECULES CAMS 0.002 0.033 High 
VIRAL MYOCARDITIS 0.009 0.033 High 
COMPLEMENT AND COAGULATION 
CASCADES 0.010 0.032 High 
RETINOL METABOLISM 0.008 0.053 High 
CYTOKINE CYTOKINE RECEPTOR 
INTERACTION 0.001 0.052 High 
SYSTEMIC LUPUS ERYTHEMATOSUS 0.007 0.054 High 
LEISHMANIA INFECTION 0.005 0.064 High 
SPLICEOSOME 0.000 0.000 Low 
RNA DEGRADATION 0.000 0.000 Low 
HOMOLOGOUS RECOMBINATION 0.000 0.000 Low 
UBIQUITIN MEDIATED PROTEOLYSIS 0.000 0.000 Low 
CELL CYCLE 0.000 0.001 Low 
N-GLYCAN BIOSYNTHESIS 0.000 0.004 Low 
PARKINSONS DISEASE 0.000 0.006 Low 
RNA POLYMERASE 0.003 0.007 Low 
LYSINE DEGRADATION 0.000 0.009 Low 
HUNTINGTONS DISEASE 0.000 0.013 Low 
PROTEASOME 0.004 0.018 Low 
TERPENOID BACKBONE BIOSYNTHESIS 0.003 0.017 Low 
OXIDATIVE PHOSPHORYLATION 0.000 0.016 Low 
AMINOACYL TRNA BIOSYNTHESIS 0.000 0.015 Low 
RIBOSOME 0.000 0.018 Low 
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Table 1. The output of the Gene Set Enrichment Analysis (GSEA) for 
CpGs with high or low MV.  
 
In Table 1 shows that the CpGs with high MV values are usually 
associated with immunological pathways (e.g. allograft rejection, 
graft vs host disease, autoimmune thyroid response, diabetes I disease, 
etc.), while CpGs with low MV values are associated with basic 
cellular functions (e.g. homologous recombination, spliceosome, cell 
cycle, RNA degradation, etc.). These findings confirm the existence 
of a biological role for the inter-individual methylation variation of 
CpGs. 
 
4.3 CpGs under ancient selective pressure show low MV 
 
In order to evaluate the presence of a correlation between evolution 
and CpGs inter-individual methylation variation, two different types 
of evolutionary signatures were chosen: ancient and recent selective 
pressure signals. The first one is commonly detected by analyzing 
inter-species base conservation (Cooper et al. 2005) and the second 
one by analyzing intra-species SNPs conservation (Li et al. 2014). In 
particular, in this thesis, the Genomic Evolutionary Rate Profiling - 
Rejected Substitutions (GERP-RS) was chosen as signal of ancient 
selective pressure (Cooper et al. 2005) and a pool of measures of 
recent selective pressure in human population (see Materials and 
methods section) as signal of recent selective pressure (Li et al. 2014).  
GERP-RS scores near zero reveal no DNA base substitution deficit 
during mammals’ evolution and no conservation, while positive 
GERP-RS scores represent a substitution deficit and the presence of 
nucleotide conservation. Figure 5 shows CpGs GERP-RS values 
divided into quartiles and plotted with the correspondent MV value.  
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Figure 5. Boxplots of positive GERP-RS scores quartiles and their 
relative MV. 
 
I found the presence of an inverse relationship between GERP-RS 
score and MV (One-Way Test, p-value < 2.2*10-16). In brief, CpGs in 
genomic regions more conserved during evolution (located in the 
higher quartile of GERP-RS score) show the lowest level of MV 
among individuals. 
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4.4 CpGs under recent selective pressure show low MV 
 
Many different measures of recent selective pressure have been 
suggested (Vitti et al. 2013), but, unfortunately, none of them seems 
to be fully informative. To assess also the presence of recent selective 
pressure signals on methylation data, I decided to use an ensemble of 
methods able to calculate SNPs conservation among populations (Li 
et al. 2014). 
dbPSHP database (http://jjwanglab.org/dbpshp) offers different 
measures combined together to assess the presence of recent selective 
pressure on SNPs in human populations (Li et al. 2014). 
To achieve a more conservative approach, SNPs overcoming the 
threshold for each measure were chosen as a signal of recent selective 
pressure. SNPs data from other two Caucasian populations were 
downloaded as a reference list to assess the MV values trend of CpGs 
under recent selective pressure. Since recent selective signals are 
population specific, I selected only SNPs under recent selective 
pressure in TSI (Tuscans in Italy) and CEU (Utah Residents with 
Northern and Western Ancestry) because genetically less distant from 
my dataset. In particular, 124 SNPs under recent selective pressure in 
TSI and 135 in CEU were obtained from the dbPSHP database. For 
each downloaded SNP, the CpGs localized in a region of 2000 base 
pair around them were identified. Eventually, I identified 272 CpGs in 
TSI and 328 in CEU and they were named as Recent Selective 
Pressure CpGs (RSP-CpGs). Figure 6 shows MV values of RSP-CpGs 
compared to those who were not classified as recent (named as Not 
RSP-CpGs) in the two populations.  
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Figure 6. Boxplots of MV values in RSP-CpGs (blue) and Not RSP-
CpGs (red) for the two populations (TSI and CEU). 
 
In regions under recent selective pressure (RSP-CpGs) the MV values 
were lower if compared with Not RSP-CpGs (RSP-CpGs TSI MV 
mean = 0.027, Not RSP-CpGs TSI MV mean = 0.035; RSP-CpGs 
CEU MV mean = 0.031, Not RSP-CpGs CEU MV mean = 0.035; 
Bonferroni corrected T-test analysis p-value < 1.4*10-10). Because the 
two datasets (CEU and TSI) differ for length from the Not RSP-CpGs 
datasets, I also implemented a bootstrapping analysis that confirmed 
the previous results (bootstrap analysis based on 10000 Monte Carlo 
simulations, TSI = p-value < 1*10-4, CEU = p-value < 3*10-3). Figure 
7 shows the bootstrapping density plot of 10000 random resampling 
of MV values from the EPIC-Italy dataset. In particular, RSP-CpGs 
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MV values were compared with 10000 samples of the same 
population size (272 CpGs for TSI and 328 CpGs for CEU), randomly 
extracted from the group of Not RSP-CpGs. 
 
 
 
 
Figure 7. Bootstrapping density plot. On the x-axis is showed the MV 
values, while on the y-axis the density of the distribution. Red and 
blue lines show CEU and TSI MV mean respectively, while red and 
blue curves represent the CEU and TSI random resampling 
distribution. P-values are indicated on the right. 
 
To confirm that the 272 TSI RSP-CpGs were really only associated 
with recent and not with ancient selective pressure, a new analysis 
using GERP-RS score was performed. No differences were found in 
terms of GERP-RS scores between RSP-CpGs and Not RSP-CpGs (T-
test = NS). This demonstrated that even if the two selective pressure 
signals showed an association with MV values, they are probably the 
reflection of two different phenomena. 
 
4.5 Cancers show high MV 
 
In the second part of this thesis, in order to explore the MV trend in 
cancer, methylomes data of four different cancer tissues freely 
available on TGCA were exploited. In particular, breast cancer dataset 
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(BRCA), liver cancer dataset (LIHC), bladder cancer dataset (BLCA) 
and kidney cancer dataset (KIRC) were used. In each dataset are 
present cancer methylomes and healthy control methylomes. 
Usually, cancer tissues show higher genetic heterogeneity than 
healthy ones (Hansen et al. 2011). This phenomenon could lead to an 
increase in inter-individual methylation variation. To test whether this 
was true also in these four datasets, the MV between healthy and 
cancer tissues was analyzed. Figure 8 shows the distribution of MV 
between the cancer tissues and the corresponding healthy controls.  
 
 
 
 
Figure 8. Boxplots of CpGs MV values in the different datasets. Red 
and blue colors are used to indicate cancer and controls respectively. 
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I found that all the cancers show higher MV than the controls 
(Pairwise t-test p-value < 2.2*10-16).  
 
4.6 Correlations between MV values are increased in cancers 
 
The increase in MV in all the cancer tissues could indicate that this 
phenomenon could be tissue independent. To test this hypothesis, an 
analysis of the correlations between different tissues, both in cancer 
and in healthy samples was performed. Figure 9 shows correlation 
matrices between datasets in healthy and cancer tissues.  
 
 
 
 
Figure 9. Plots of the correlation matrices between MV values in 
controls (blue) and cancer (red) samples. Correlation values are 
indicated in white in each square. 
 
Good correlations between MVs in cancer tissues (min=0.7, 
max=0.84) higher than correlations in healthy ones (min=0.56, 
max=0.67) were found. Despite the biological differences between 
these tissues, the four MV distributions show a good correlation 
between them even in the healthy datasets. To evaluate the 
significance of these correlations, tests for association between paired 
MV distributions using “Pearson's product moment correlation 
coefficient” were performed. All the tests show a p-value < 2.2*10-16. 
These results show that, regardless of the tissue, the increase in MV 
leads to an increase in correlation among cancers. 
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4.7 DM-CpGs show high MV 
 
Finally, an analysis to identify Differentially Methylated - CpGs 
(DM-CpGs) between cancers and control samples on each dataset was 
performed. To identify DM-CpGs, a linear regression model on R 
(limma) (Ritchie et al. 2015), using m-values, with adjusted p-value < 
0.01 and logFC > 2 was performed. Figure 10 shows the MV trend of 
the DM-CpGs in the different datasets between cancer and control 
samples. 
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Figure 10. Boxplots of MV values for DM-CpGs and Not DM-CpGs 
in cancer (red) and control (blue) samples. Each dataset is plotted 
separately. 
 
I found that DM-CpGs, regardless of the tissue and of the status, have 
statistically higher MV than Not DM-CpGs (Pairwise t-test p-value < 
2.2*10-16). Furthermore, even if MV differences were greater in 
cancer tissues than in healthy ones, DM-CpGs show higher MV than 
Not DM-CpGs also in the control samples. These results assess the 
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presence of variably methylated CpGs that, also in healthy samples, 
represent the most variable part of the entire set. These CpGs became 
DM-CpGs in cancer but, still in healthy controls, they express higher 
inter-individual methylation variation. 
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5. DISCUSSION 
 
Epigenetics is a field of growing interest among researchers involved 
in different medical areas (e.g. cell biology, molecular medicine, 
cancer, physiology, behavior, development, morphology).  
Previous studies analyzed the DNA methylation variation in healthy 
individuals (Bock et al. 2008). While the presence of a stochastic 
component of such variation is undeniable, its relationship with 
demographic variables such as gender (Zhang et al. 2011), age (Jones 
et al. 2015), and smoking behavior (Ambatipudi et al. 2016) is well 
established. Similarly, it has been also demonstrated the functional 
impact of this variation on phenotypes (Peaston and Whitelaw 2006). 
DNA methylation variation has been also hypothesized to influence 
response to drug treatments, as well as susceptibility to common 
diseases (Heyn et al. 2013; Chatterjee et al. 2015). Furthermore, DNA 
methylation has been also described to vary between ethnicities 
(Zhang et al. 2011; Coit et al. 2015; Kader and Ghai 2016).  
Epigenetics is also achieving a role in our understanding of natural 
selection and evolution. In a recent paper (Burggren et al. 2016), the 
authors established that about 1% of epigenetics studies were 
dedicated to investigating relationships with natural selection and 
evolution. Most of these papers treat the conservation of DNA 
methylation among species (Lam et al. 2012; Gokhman et al. 2014), 
while others treat the species-specific DNA methylation (Zeng et al. 
2012). 
In this thesis, I decided to focus my attention on inter-individual 
methylation variation (denoted as MV), because it is a not well-
characterized factor that could profoundly influence methylation array 
results and gene transcription analyses.  
In detail, in the first part, I investigated the methylation variation 
among healthy individuals to find its possible relationship with 
genomic features and evolutionary signatures (Palumbo et al. 2018). 
To this aim, I exploited the methylation data from the Italian section 
of the EPIC cohort (Riboli et al. 2002).	I used beta-values previously 
normalized using GenomeStudio software by Illumina. I am aware 
that other software is now available for a more efficient 
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normalization. However, GenomeStudio still remains reliable and 
widely used by the scientific community (Pidsley et al. 2013).  
I decided to use, according to previously published studies (Lam et al. 
2012; Chatterjee et al. 2015; Jiang et al. 2015), the standard deviation 
as a measure of inter-individual methylation variation. The MV values 
distribution in my cohort was perfectly in agreement with that 
available in the literature (Chatterjee et al. 2015; Jiang et al. 2015). To 
find the possible relationship between inter-individual methylation 
variation and genomic features, I decided to exploit the CpGs cluster 
density. This parameter has been previously used as a suitable method 
to identify biologically-relevant structures (Price et al. 2013). With 
this approach, I found a strong relationship between MV and CpG 
cluster density. Indeed, HC regions showed low MV levels, while IC 
and LC regions showed increasingly higher levels. This result is in 
agreement with the current knowledge of the direct correlation 
between methylation levels and CpGs cluster density (Bock et al. 
2008; Lam et al. 2012; Jiang et al. 2015). As said before, to date, only 
a few papers have focused on inter-individual methylation variation. 
Wagner and colleagues (Wagner et al. 2014) showed a low inter-
individual methylation variation in CpGs situated near a TSS and 
highly variable CpGs placed far away from it. This finding is in 
agreement with mine because high-density CpG clusters are usually 
situated near a TSS (Wagner et al. 2014). A possible reason for this 
phenomenon could be found in the global hypomethylation of HC 
regions, which could cause small inter-individual methylation 
variations (Taudt et al. 2016). However, it should be mentioned that 
CpGs with the highest MV, which fall in IC and LC regions, are 
poorly probed by Illumina 450K array and have a propensity to fall 
outside the CpG Islands (Taudt et al. 2016). It has been found, in 
Acute Lymphoid Leukemia cells, that CpGs falling outside CpG 
Islands exhibit significantly more variation in methylation levels than 
those falling within the CpG Islands (Milani et al. 2010). Therefore, 
my results are consistent with the literature, because the highest 
number of CpGs falling outside an Island belongs to both LC or IC 
classes (Price et al. 2013). Eventually, also Bock and colleagues 
(Bock et al. 2008) demonstrated that CpGs rich regions (HC) show 
low and similar levels of MV while CpGs poor regions (LC) show 
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high levels of MV. With this knowledge, it is possible to assert that 
my result is fully in agreement with the current literature. 
To investigate a possible association between inter-individual 
methylation variation and biological pathways, I decided to use a 
GSEA approach. I found an enrichment of pathways associated with 
the immune system in highly variable CpGs, while I found an 
enrichment of pathways associated with basic cellular functions in 
CpGs with a low inter-individual variation. A previous paper studied 
CpGs methylation in three different human populations, showing 439 
Differential Methylated CpGs (DM-CpGs) between the groups (Heyn 
et al. 2013). Remarkably, genes harboring these population-different 
CpGs in their promoters are liable for xenobiotic metabolism and 
immune response factors. Another recent study investigated the gene 
expression of blood samples acquired by 200 healthy controls, and it 
demonstrated that highly variable transcripts among individuals were 
enriched for genes mostly involved in mediating immune-related 
processes (Ecker et al. 2017). A possible reason for these results could 
be found in the biology of the blood samples. Since in these samples 
DNA molecules are obtained from white blood cells, it is reasonable 
to imagine that variable methylation signals could partly help us to 
face different immunological situations, with some variations between 
individuals. The expression of genes participating in the immune 
response is very variable in a population. Indeed, each individual 
interacts with different xenobiotics or pathogens during his life which 
stimulate the immune system in different ways (Lim et al. 2013). 
Furthermore, I also inspected the MV of CpGs that are conserved 
among species positing that they likely have a biologically relevant 
function. I discovered that CpGs more conserved during evolution 
showed the lowest values of MV. A recent study showed, comparing 
human-mouse methylation, that methylation correlates, although 
weakly, with sequence conservation (Xin et al. 2011). Studying the 
association between genetics, DNA methylation, and expression in 
fibroblasts, other researchers demonstrated that CpGs with low inter-
individual methylation variation displayed a good degree of sequence 
conservation (Wagner et al. 2014). I then verified the assumption of a 
possible association between recent selective pressure and inter-
individual methylation variation among individuals of the same 
population. I found that inter-individual methylation variation was 
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lower in regions under recent selective pressure compared to the other 
ones. A possible explanation of this finding is that my results could 
indicate a recent evolutionary fixation of the methylation values. In 
particular, the inter-individual methylation fixation could point to both 
a pure epigenetic fixation or to a genetic variation associated with a 
specific methylation pattern (Klironomos et al. 2013). In the first 
scenario, it might be possible that a stochastic methylation pattern 
could have enhanced, somehow, the human adaptation by providing 
an advantageous phenotype in a specific environment. In the second 
scenario, it could be possible that an advantageous genetic mutation is 
related to a specific methylation pattern, mostly because it is the only 
possible one for that specific mutation. It is worth to remark that some 
authors demonstrated how epigenetic mechanisms can drive genetic 
changes (Jablonka 2013; Skinner et al. 2015), while others suggested 
that genetic variations could determine DNA methylation differences, 
and, eventually, proposed that different methylated CpGs could work 
as evolutionary mediators between the genetic code and the 
phenotypic variability (Heyn et al. 2013). 
Inspired by the previous results on this topic (Palumbo et al. 2018), I 
decided to continue the investigation on inter-individual methylation 
variation trend among individuals but, this time, adding new factors: 
more tissues and different health status. In brief, in the second part of 
my thesis, I analyzed the methylation variation among healthy and 
not-healthy individuals in different tissues to investigate its possible 
relationship with the health status. 
To this aim, I decided to use TCGA cancer and control methylomes of 
four datasets: BRCA, LIHC, BLCA, and KIRC. Each one of these 
datasets is composed of healthy and cancer samples; this allowed me 
to analyze MV differences between the two groups in all the datasets. 
It is well known that the health status (You and Jones 2012; 
Teschendorff et al. 2014; Chen et al. 2016) and the tissue (Byun et al. 
2009) are important biological factors of methylation variation. To 
avoid any bias, the methylomes data were neither mixed together nor 
analyzed as one dataset due to the presence of dataset dependent 
confounding factors: sex, age, and ethnicity are not equally distributed 
among the datasets. 
To assess the differences in health status among the datasets, I 
compared MV distribution between cancer samples and controls. As 
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expected, I found a strong difference in MV distribution and all the 
cancer samples show higher MV than the controls regardless of the 
original tissue. Even if it is still unclear who is the main actor that 
change the methylation patterns during carcinogenesis, it is known 
that methylation variation is increased in cancers (You and Jones 
2012; Teschendorff et al. 2014; Chen et al. 2016). 
Indeed, Chen and colleagues (Chen et al. 2016), using fetal tissues, 
found tissue-independent patterns of DNA methylation in cancers 
especially in CpG Island, gene promoters and gene bodies. Instead, 
Teschendorff and colleagues (Teschendorff et al. 2014) demonstrated 
an increase in variation and co-variation of DNA methylation in 
normal cells transforming in cancer cells. Taken together, these 
studies are in accordance with my result: cancers show an increase in 
inter-individual methylation variation in a tissue-independent manner. 
As proposed by Chen (Chen et al. 2016), I decided to assess whether a 
global increase in MV could lead also in an increase in MV 
correlation among tissues in the two groups (cancer and controls). I 
found that cancers correlate better in MV among the tissues than the 
controls. The increase in correlation among cancers allows me to 
hypothesize the presence of a modifier factor transcending tissues. 
Indeed proofs of correlation between DNA context and methylation 
pattern were previously proposed (You and Jones 2012; Aryee et al. 
2013).  
Finally, I decided to test the MV trend in Differentially Methylated - 
CpGs (DM-CpGs). The systematic investigation of DM-CpGs or 
Differentially Methylated Regions (DMRs) is a common practice to 
detect deregulated genes in cancers (Hansen et al. 2011; Wang et al. 
2017). For this aim, I used a linear regression approach (limma) 
(Ritchie et al. 2015) on R: a common method for detecting DM-CpGs 
in methylation arrays (Smyth 2005). I performed four distinct 
analyses on the four different tissues between control samples and 
cancer samples. I found, with a strong statistical significance, that 
DM-CpGs always show higher MV than the remaining CpGs, also in 
the healthy samples. This result underlines that DM-CpGs, regardless 
of the tissue, the sex, the age, the ethnicity, and the health status, are 
highly variable among individuals. This finding is in accordance with 
the recent work of Wang and colleagues (Wang et al. 2017) where a 
high inter-individual variation was found on DMRs and, to perform a 
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better analysis, they eventually suggest to use a new method that takes 
in account the MV in the dataset. Unfortunately, it is only possible to 
hypothesize a biological meaning of these DM-CpGs with high MV 
also in healthy samples. It seems that DM-CpGs are very unstable 
elements also before the cancer onset. DNA context, regulatory 
motifs, and other biological factors could be the actors of this 
phenomenon. However, new methods seem to deal with the problem 
of age and cancer variability in DMRs (Phipson and Oshlack 2014). 
This new awareness of the importance of inter-individual methylation 
variation motivates me to continue my work on this topic.
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6. CONCLUSIONS 
 
One of the most studied epigenetic mechanisms of gene regulation is 
DNA methylation. During the last decade, many researchers focused 
their attention on studying methylation signals among populations. 
This phenomenon created, over the years, many public data about 
DNA methylation status. 
In this thesis, novel factors influencing inter-individual methylation 
variation (MV) were explored. In particular, evolutionary constraints, 
genomic landscape, biological pathways, and health status were 
investigated. In the first part, methylation data from EPIC-Italy cohort 
were used to assess MV trend in relation to evolution, genomic 
landscape, and its biological function. In the second part, methylation 
data of 4 tissues from TCGA were used to assess MV trend in relation 
to health status. Exploiting EPIC-Italy dataset, I found a good 
association between MV and CpGs cluster density. In particular, 
CpGs belonging to High-density CpGs (HC) group showed the lowest 
MV values while those belonging to Low-density CpGs (LC) group 
showed the highest ones. Furthermore, a GSEA approach was 
performed to assess the biological pathways associated with high and 
low MV values. Eighteen enriched pathways were found associated 
with high MV values and most of them are related to immunological 
functions. Finally, I investigated both signals of ancient and recent 
selective pressure in relation to MV. I found a strong association 
between MV and signals of both ancient and recent selective pressure. 
Indeed, CpGs under ancient or recent selective pressure show lower 
MV than the remaining ones. 
In the second part of this thesis, the MV trend in relation to health 
status was assessed. I found that, regardless of the tissue, cancers 
samples always show higher MV than control ones and this 
phenomenon leads to an increase in correlation among cancer tissues. 
Furthermore, analyzing Differentially Methylated - CpGs (DM-CpGs) 
between cancer and control samples in each tissue, I found, 
surprisingly, that the DM-CpGs always show higher MV than the Not 
DM-CpGs, regardless of the tissue and of the health status.  
In brief, I demonstrated that inter-individual methylation variation is 
correlated with many biological factors. According to me, a better 
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investigation of all possible influencing factors is required to fully 
understand the hidden epigenetic mechanisms of gene regulation. In 
particular, the last result paves the way to a better comprehension of 
the role of the DM-CpGs in cancer. 
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